We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+65.27%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$5.03B
AUM Growth
+$1.32B
Cap. Flow
-$125M
Cap. Flow %
-2.48%
Top 10 Hldgs %
53.64%
Holding
139
New
31
Increased
25
Reduced
19
Closed
25

Top Buys

Rank Stock Value
1
KRRO icon
Korro Bio
KRRO
+$47.2M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$34M
3
ANAB icon
AnaptysBio
ANAB
+$23.6M
4
QTNT
Quotient Limited Ordinary Shares
QTNT
+$20.7M
5
ZGNX
Zogenix, Inc.
ZGNX
+$20.4M

Top Sells

Rank Stock Value
1
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$104M
2
SLDB icon
Solid Biosciences
SLDB
+$69.8M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$46.8M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$36.4M
5
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$33.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.17%
2 Financials 0.38%
3 Technology 0.12%
4 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
YMAB
51
DELISTED
Y-mAbs Therapeutics
YMAB
$17.6M 0.35%
562,237
-292,703
-34% -$8.66M
TXG icon
52
10x Genomics
TXG
$5.88B
$16.8M 0.33%
220,000
– –
ARVN icon
53
Arvinas
ARVN
$530M
$16.4M 0.33%
+400,000
New +$11.7M
ANAB icon
54
AnaptysBio
ANAB
$1.54B
$16.3M 0.32%
+1,000,000
New +$23.6M
AUPH icon
55
Aurinia Pharmaceuticals
AUPH
$1.95B
$14.5M 0.29%
+716,666
New +$6.6M
RVNC
56
DELISTED
Revance Therapeutics, Inc.
RVNC
$13.3M 0.26%
+820,377
New +$12.7M
ICPT
57
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$12.1M 0.24%
97,600
– –
MORF
58
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$11.2M 0.22%
650,000
– –
SCPE.U
59
DELISTED
SC Health Corporation Units, each consisting of one Class A ordinary share, $0.0001 par value, and o
SCPE.U
$10.4M 0.21%
1,000,000
– –
VRAY
60
DELISTED
ViewRay, Inc.
VRAY
$10.3M 0.21%
2,451,748
– –
FULC icon
61
Fulcrum Therapeutics
FULC
$241M
$9.98M 0.2%
600,000
– –
IMVTU
62
DELISTED
Immunovant, Inc. Units
IMVTU
$9.95M 0.2%
+400,000
New +$8.62M
HCAT icon
63
Health Catalyst
HCAT
$160M
$9.84M 0.2%
283,698
+72,774
+35% +$2.41M
MOTS
64
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$9.64M 0.19%
14,035
– –
ADPT icon
65
Adaptive Biotechnologies
ADPT
$3.61B
$9.13M 0.18%
305,000
+10,000
+3% +$287K
ALEC icon
66
Alector
ALEC
$169M
$8.82M 0.18%
511,731
– –
COLL icon
67
Collegium Pharmaceutical
COLL
$1.18B
$8.67M 0.17%
+421,272
New +$7.02M
IDYA icon
68
IDEAYA Biosciences
IDYA
$3.43B
$8.56M 0.17%
1,141,484
– –
ISEE
69
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.5M 0.17%
+990,289
New +$3.54M
CERN
70
DELISTED
Cerner Corp
CERN
$7.71M 0.15%
105,000
+40,000
+62% +$2.77M
ZBH icon
71
Zimmer Biomet
ZBH
$18.8B
$7.48M 0.15%
51,500
– –
NGNE icon
72
Neurogene
NGNE
$672M
$6.16M 0.12%
+25,000
New +$2.49M
VCRA
73
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$6.15M 0.12%
296,420
+196,616
+197% +$4.31M
VERU icon
74
Veru
VERU
$35.5M
$5.53M 0.11%
165,000
– –
NVTA
75
DELISTED
Invitae Corporation
NVTA
$5.42M 0.11%
336,308
-861,874
-72% -$15.2M
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2019 Portfolio in Review

As of Q4 2019, Perceptive Advisors held 139 positions worth $5.03B, up 36% from $3.71B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Perceptive Advisors's Q4 2019 filing shows 31 new, 25 increased, 19 reduced and 25 closed positions. Its largest new stake was Korro Bio: 60,686 shares worth $49.8M. The largest sale was Dova Pharmaceuticals, Inc. Common Stock, an estimated $104M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Financials and Technology.

  • Perceptive Advisors's largest Q4 2019 buy was Korro Bio: 60,686 shares worth $49.8M.
  • Perceptive Advisors added most to Quotient Limited Ordinary Shares in Q4 2019, an estimated $20.7M increase.
  • Perceptive Advisors's biggest Q4 2019 reduction was Neurocrine Biosciences, cutting an estimated $46.8M.
  • Perceptive Advisors fully exited Dova Pharmaceuticals, Inc. Common Stock in Q4 2019, selling an estimated $104M.
  • Perceptive Advisors's ten largest holdings make up 54% of its $5.03B portfolio in Q4 2019.
  • Perceptive Advisors opened 31 new positions and closed 25 in Q4 2019.
  • Perceptive Advisors's portfolio value rose 36% quarter-over-quarter to $5.03B.

Based on Perceptive Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.